MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Watch List: Layoffs of 10% or More, Strategic Corporate Review, Delisting, Regulatory, Financial and/or Legal Issues
Eyenovia, Inc. (NASDAQ: EYEN)*
Organization & Developments: Eyenovia
Parents
Eyenovia, Inc. (NASDAQ: EYEN)*
Children
*Eyenovia inc. is a clinical stage ophthalmic biopharmaceutical company.
*Eyenovia is a small operation, employing only ~25
*Focuses on eye diseases using its Microdose Array Print platform technology.
2019: Eyenovia: A High Risk/High Reward Small Cap_seekingalpha.com
2020: Circling Back On Eyenovia
2020: Eyenovia: Continued Pipeline Progress, Attractive Valuation
2022: Eyenovia is set to release topline data of MicroLine from its VISION-2 trial to treat presbyopia. Presbyopia is a progressive disease that causes the hardening of the lens and inhibits an eye's ability to focus and affects 128 million Americans.
2024: Eyenovia Shares Plummet 70% After It Drops Lead Program
2024: Eyenovia stock plummets following Phase III myopia trial failure
2024: Eyenovia to end eye drug study, cut 50% of its workforce
Jumps
Finance & Acquisitions: Eyenovia
Key People: Eyenovia